<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825808</url>
  </required_header>
  <id_info>
    <org_study_id>Local/2021/DR-01</org_study_id>
    <nct_id>NCT04825808</nct_id>
  </id_info>
  <brief_title>Detailed Clinical and MRI Characteristics in Primary Non-traumatic Convexity Subarachnoid Haemorrhage Elderly Patients.</brief_title>
  <acronym>cSAH</acronym>
  <official_title>Detailed Clinical and MRI Characteristics in Primary Non-traumatic Convexity Subarachnoid Haemorrhage Elderly Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient focal neurological episode (TFNE) is the most frequent presenting symptom of&#xD;
      convexity subarachnoid haemorrhage (cSAH) in elderly patients with non-traumatic cSAH with&#xD;
      suspected, possible or probable cerebral amyloid angiopathy (CAA). The aim of our study was&#xD;
      to analyse in detail clinical and MRI characteristics in these patients.&#xD;
&#xD;
      Methods: We performed a retrospective study analysing baseline, acute clinical symptom (TFNE&#xD;
      and headache), and MRI characteristics (acute cSAH and chronic CAA features) of consecutive&#xD;
      elderly (≥55 years) patients, recruited and registered in the stroke database, between june&#xD;
      2008 and october 2020 of two centres (Nîmes and Montpellier University Hospital, France),&#xD;
      presenting with cSAH with suspected, possible, or probable CAA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">March 29, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>Extent of acute cSAH (number of sulci, focal [≤3 sulci] or diffuse [&gt;3 sulci], surface)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>the multifocality of acute cSAH (as described for cortical superficial siderosis (CSS)), sulci involved by cSAH, CSS presence, CSS extent (focal, ≤3 sulci; diffuse &gt;3 sulci)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>cerebral microbleeds (CMB, &lt;10 mm) presence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>cerebral microbleeds number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>cerebral microbleeds categorisation (according to the Microbleed Anatomical Rating Scale),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>presence and number of chronic lobar intracerebral haemorrhage (ICH) (&gt;10 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of MRI</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>Extent of white matter hyperintensities (periventricular Fazekas scale 0-3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>Transient focal neurological episode (TFNE) presence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>number of TFNE preceding MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>TFNE symptoms (sensory, motor, visual, speech; positive or negative symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>Presence and speed of spreading TFNE symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>Correlation of TFNE symptoms to cSAH localisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>headache (Yes/No)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical parameters</measure>
    <time_frame>day of the diagnosis</time_frame>
    <description>antiepileptic drugs (AED) introduction and type of AED introduced</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Cerebral Amyloid Angiopathy</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Consecutive elderly (≥55 years) patients, recruited and registered in the stroke database of two centres (Nîmes University Hospital and Montpellier University Hospital, France), presenting with cSAH with suspected, possible, or probable CAA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual care</intervention_name>
    <description>according to recommendations</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive elderly (≥55 years) patients, recruited and registered in the stroke database&#xD;
        of two centres (Nîmes University Hospital and Montpellier University Hospital, France),&#xD;
        presenting with cSAH with suspected, possible, or probable CAA.&#xD;
&#xD;
        The patients were classified as possible or probable CAA according to the modified Boston&#xD;
        criteria. Since cortical superficial siderosis (CSS), incorporated in the modified Boston&#xD;
        criteria, is probable a result of an earlier acute cSAH, we considered patients with acute&#xD;
        cSAH in the absence of other typical CAA-related haemorragic features as patients with&#xD;
        suspected CAA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥55 years of age,&#xD;
&#xD;
          -  acute symptomatic cSAH based on FLAIR and T2*-weighted imaging performed within one&#xD;
             month of symptom onset, recent trauma,&#xD;
&#xD;
          -  anticoagulation treatment, pathological blood coagulation tests (activated partial&#xD;
             thromboplastin time [aPTT] ratio=patient's aPTT/normal control aPTT] &gt;1.2; or partial&#xD;
             thromboplastin time [PTT] &lt;75%) or platelet count (&lt;100 x 109/L),&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  exclusion of underlying non-CAA cSAH causes (e.g. reversible cerebral vasoconstriction&#xD;
             syndrome, trauma, cerebral venous sinus thrombosus, aneurysm, primary angiitis of the&#xD;
             central nervous system, anticoagulation treatment, pathological blood coagulation&#xD;
             tests)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anissa MEGZARI</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

